A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Trial Profile

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Paliperidone (Primary) ; Aripiprazole; Haloperidol; Olanzapine; Paliperidone; Perphenazine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PRIDE
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 20 May 2015 Results presented at the 168th Annual Meeting of the American Psychiatric Association.
    • 11 May 2015 According to a Janssen Pharmaceuticals media release, the U.S. FDA issued a Complete Response letter regarding the sNDA filed in July 2014 to include data from this study to update the INVEGA SUSTENNA label.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top